A trial listing marked "recruiting" on ClinicalTrials.gov does not guarantee you can enroll, that the study will complete, or even that the status information is current. 31% of trial listings had incorrect recruitment status or documented delays exceeding one year before the registry reflected a study had ended, according to the National Center for Biotechnology Information, and even among concluded trials, the median delay between study completion and the registry update was 141 days. If you or a family member has looked up an Alzheimer's trial hoping to participate, the listings can feel like a clear path forward. In reality, the gap between a "recruiting" label and an actual enrollment slot is wide, shaped by enrollment bottlenecks, screening failures, funding constraints, and publication delays that the listing itself never mentions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Check eligibility on ClinicalTrials.gov’s official study page — Use this page to check the study’s participation requirements.
- Check eligibility on NIH’s official study page — Use this page to check the study’s participation requirements.
Table of Contents
- What "Recruiting" Status Really Means
- The Screening Funnel—Why Most People Don't Make It Through
- Racial and Demographic Screening Disparities
- Why Timelines Slip and Enrollment Extends
- Funding Gaps and Trial Discontinuation
- "Enrolling by Invitation"—A Status That Limits Access
- Frequently Asked Questions
What "Recruiting" Status Really Means
When a trial shows "recruiting," it signals that the research site is *actively seeking* participants—but not that it has capacity to accept you immediately or that screened candidates will meet eligibility criteria. Only 1% of potentially eligible participants are typically engaged by the clinical trial ecosystem overall, and the disparity is stark in Alzheimer's disease: 71% of phase III NCI-approved trials and over 40% of NCI-sponsored trials close without meeting their enrollment goals.
The lag between a study's actual status and what appears online also matters. Site activation in Alzheimer's trials commonly experiences heavy documentation burdens and low patient enrollment in the first 60 days, despite published activation timelines suggesting faster enrollment rates. This means a listing can look current while enrollment has actually stalled weeks earlier.
The Screening Funnel—Why Most People Don't Make It Through
Even if you meet the broad eligibility criteria listed, screening often narrows the pool dramatically. In Alzheimer's trials, 62% of screen failures stem from participant-related factors—lack of interest, scheduling conflicts, illness—while 57% result from failing eligibility criteria, creating a funnel that substantially reduces the number of people who actually enroll.
The published eligibility criteria tell only part of the story. You may pass the initial screening questions but fail bloodwork, cognitive testing, imaging requirements, or medication interactions discovered later. Studies also impose practical demands—regular site visits, time commitments, or travel distance—that screen out eligible people for reasons the listing does not capture.
Racial and Demographic Screening Disparities
The risk of screening failure is not equally distributed. In Alzheimer's trials, 68.7% of screen failures due to ineligibility involved minority older adults (Hispanic, Black, and Asian participants), while 71% of scheduling failures were White participants.
This pattern reveals that published eligibility criteria do not predict equitable enrollment outcomes and that systemic barriers—access, transportation, competing health care appointments, or medical mistrust—often affect enrollment differently across racial groups. The listing cannot show you this disparity. If you are a member of a racial or ethnic minority group seeking an Alzheimer's trial, your individual chances of progressing through screening differ from those of White participants in the same study, even when the posted criteria appear identical.
Why Timelines Slip and Enrollment Extends
A trial's listed start and completion dates are based on planned enrollment rates. In practice, less than 47% of Alzheimer's trials complete enrollment on schedule, with 53% requiring extended timelines and one in six taking more than twice as long as originally planned, often due to site activation bottlenecks and screening workflow delays.
If you see a trial closing enrollment in 12 months, plan for the possibility that enrollment could extend to 24 months or longer. A delayed enrollment phase means waiting periods stretch, and if you have advancing cognitive decline or other health changes, your ability to participate may shift by the time the trial finally enrolls.
Funding Gaps and Trial Discontinuation
Even studies that advance through early phases remain subject to funding decisions. Federal agencies reserve the right to decline award continuation phases, and cost overruns frequently exhaust budgets before trials reach enrollment targets.
A trial listed as recruiting does not guarantee that funding will sustain it to completion or that results will be published and available to participants. This is particularly relevant for longer-term Alzheimer's studies, where follow-up periods span years. A trial that enters your community as "recruiting" may be halted mid-way through your participation if funding ends, leaving both participants and researchers without the results they expected.
"Enrolling by Invitation"—A Status That Limits Access
Some listings show "enrolling by invitation only," which means the trial restricts enrollment to a population pre-selected by researchers rather than remaining open to all who meet eligibility criteria. This status does not appear prominently in a summary and often surprises interested participants.
If you find a trial you want to join and it carries this status, contact the trial site directly—sometimes the restriction is geographic, based on prior research participation, or tied to recruitment quotas already filled. Do not assume that a good fit with the listed criteria automatically means you can enroll.
Frequently Asked Questions
Should I contact a trial site even if I don't perfectly match the listed criteria?
Yes. Eligibility criteria listed online are often conservative. Sites may have flexibility, or you may qualify under exceptions not mentioned in the summary. A phone call costs nothing and can clarify your actual chances.
If a trial is marked "recruiting," how long should I expect to wait before I'm enrolled?
Timelines vary widely, but plan for several months of screening and scheduling even after initial contact. If you are told enrollment will close in a few weeks, verify that directly with the site rather than relying on the listing date.
What should I do if I'm enrolled in a trial and funding is cut?
Ask your trial coordinator what funding loss would mean for your participation and whether backup funding exists. Some trials have institutional support; others depend on grant cycles. Understanding the trial's financial stability early helps you decide whether to continue.
Are there trials specifically designed for people from underrepresented racial and ethnic groups?
Some trials prioritize diversity, but this is not always stated in the listing. If equity or culturally tailored enrollment is important to you, ask the trial site whether they have targeted recruitment efforts or whether your demographic group is underrepresented in their current enrollment.
